

An accredited satellite symposium held at the 2022 HFSA Annual Scientific Meeting of the Heart Failure Society of America

FOR MORE  
INFORMATION  
GO TO:

[hfsa.org/hfsa-annual-scientific-meeting-2022](https://hfsa.org/hfsa-annual-scientific-meeting-2022)



## Fine-Tuning the Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction

**Saturday, October 1, 2022**

Registration: 6:45 PM – 7:00 PM ET

Symposium: 7:00 PM to 8:30 PM ET

This program will also be live-streamed and on-demand.

**Gaylord National  
Convention Center  
Ballroom: National Harbor 2/3**

201 Waterfront Street  
National Harbor, Maryland



**Chair**

John Teerlink, MD

**Faculty**

G. Michael Felker, MD, MHS

Robert Mentz, MD

Alanna Morris, MD, MSc

This activity is supported by an independent educational grant from Cytokinetics Incorporated.

Program management services provided by



This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.


Accredited Sponsor:  
Heart Failure Society of America



# AGENDA

- 7:00 PM Introduction  
**John Teerlink, MD (Chair)**
- 7:05 PM Worsening Heart Failure in HFrEF: Clinical Trajectory and Challenges  
**Robert Mentz, MD**
- 7:25 PM New and Emerging Therapeutic Options for WHF in HFrEF: Vericiguat and Omecamtiv Mecarbil  
**John Teerlink, MD**
- 7:50 PM HFrEF and WHF: Filling in the Treatment Gaps  
Case Presentation #1  
**Alanna Morris, MD, MSc**  
Case Presentation #2  
**G. Michael Felker, MD, MHS**
- 8:15 PM Question and Answer

## CHAIR



### **John Teerlink, MD**

Professor of Medicine  
University of California, San Francisco School of Medicine  
Director of Heart Failure  
San Francisco Veterans Affairs Medical Center  
San Francisco, California

## FACULTY



### **G. Michael Felker, MD, MHS**

Professor of Medicine  
Vice-Chief for Clinical Research, Duke Cardiology  
Director of Cardiovascular Research, DCRI  
Duke University School of Medicine  
Durham, North Carolina



### **Robert Mentz, MD**

Associate Professor of Medicine  
Associate Professor in Population Health Sciences  
Duke University School of Medicine  
Durham, North Carolina



### **Alanna Morris, MD, MSc**

Associate Professor of Medicine  
Director of Heart Failure Research  
Emory Clinical Cardiovascular Research Institute  
Atlanta, Georgia

## PROGRAM OVERVIEW

Patients with heart failure with reduced ejection fraction (HFrEF) and worsening heart failure (WHF) have high rates of death and recurrent HF hospitalization; the management of these patients is particularly challenging. While optimization of disease-modifying, guideline-directed medical therapy (GDMT) is of paramount importance, it is often not implemented due to a variety of clinician-, patient-, and system-related factors. There have been limited options for treatment of WHF; however, new and emerging therapies with distinct mechanisms of action have demonstrated effectiveness in reducing the risk of adverse HF-related outcomes, with excellent safety profiles, in patients with HFrEF and evidence of recent WHF. An increasing number of available therapies for HFrEF has therefore created a need for HF clinicians to be able to tailor medical therapy to a patient's profile. Therefore, in this program, experts will 1) provide insights into the clinical course of patients with HFrEF and WHF, 2) describe current challenges in the treatment of these patients, 3) interpret evidence with, and identify roles for, new and emerging therapies for WHF, and 4) demonstrate a personalized approach to patient management.

## ACCREDITATION AND CREDIT DESIGNATION STATEMENT



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

**Physicians:** In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the

Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of *1.5 AMA PRA Category 1 Credits™*. Learners should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.5 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

**Pharmacists:** The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.5 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-003-L04-P. To earn credit, participants must complete the online evaluation for each presentation attended and submit their NABP ID and DOB (MMDD). Once evaluations are completed, CPE will be uploaded to CPE monitor within 60 days of the close of the activity.

**Eligibility:** Registration for the 2022 HFSA Annual Scientific Meeting and an official name badge are required to attend this symposium.

This activity is supported by an independent educational grant from Cytokinetics Incorporated.

Program management services provided by

